nam special situations fund ii llc palantir series   list of ceos founders and company directors directorpedianet  list of ceos founders board members and company directors nam special situations fund ii llc palantir series  list of persons related to the company nam special situations fund ii llc palantir series  find out list of ceos founders board members and company directors of nam special situations fund ii llc palantir series  cik number irs number company address co national securities corporation  park avenue th floor new york phone number  people related to nam special situations fund ii llc palantir series  namepositionstreetcitycountrylevine davidco national asset management inc  park avenue th floornew yorkny nam special situations management llc park avenue th floor new yorkny national asset management inc park avenue th floor new yorknylerner williamco national asset management inc  park avenue th floornew yorkny nam special situations fund ii llc palantir series  on the web related companiesnam biotech fund ii llc series i nam biotech fund ii llc series iii nam biotech fund ii llc series iv nam biotech fund ii llc  series ii nam special situations fund i qp llc nam special situations fund i qp llc fbio series i nam special situations fund i qp llc lyft series iii nam special situations fund i qp llc lyft series iv nam special situations fund i qp llc palantir series  nam special situations fund i qp llc  fbio series ii nam special situations fund i qp llc  fbio series iv nam special situations fund i qp llc fbio series iii nam special situations fund i llc nam special situations fund iii llc magic leap series  namaste solar electric inc nam special situations fund ii llc palantir series   who is raising money  sec filings of fundraisings and investments in hedge funds startups and private equity companies who is raising money nam special situations fund ii llc palantir series  funding details nam special situations fund ii llc palantir series  industry pooled investment fundcik number irs number address co national securities corporation  park avenue th floor new york phone number  nam special situations fund ii llc palantir series  filings datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions new form dindefiniteyet to sellindefiniteb c csec filing directors and executives of nam special situations fund ii llc palantir series  key people in nam special situations fund ii llc palantir series   nam special situations management llc national asset management incwilliam lernerdavid levine similar companiesnamaste solar electric inc nambia rare earths inc namir strategic resources fund lp namely inc namecoach inc nam special situations fund i qp llc namaste technologies inc nam special situations fund i llc nam special situations fund iii llc magic leap series  nam special situations fund i qp llc palantir series  nam special situations fund i qp llc lyft series iii nam biotech fund ii llc series i last visited companies karamaan group fund ltd keystone active trader llc laidlaw venture partners iii llc lecere corp lecere corp  whoisraisingmoneycom daily updated news about investment into startups hedge funds and private equity companies   nam special situations fund i qp llc palantir series   who is raising money  sec filings of fundraisings and investments in hedge funds startups and private equity companies who is raising money nam special situations fund i qp llc palantir series  funding details nam special situations fund i qp llc palantir series  industry pooled investment fundcik number irs number address co national securities corporation  park avenue th floor new york phone number  nam special situations fund i qp llc palantir series  filings datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions new form dindefiniteyet to sellindefiniteb c csec filing directors and executives of nam special situations fund i qp llc palantir series  key people in nam special situations fund i qp llc palantir series   nam special situations management llc national asset management incdavid levine similar companiesnamaste solar electric inc nambia rare earths inc namir strategic resources fund lp namely inc namecoach inc nam special situations fund i qp llc namaste technologies inc nam special situations fund i llc nam special situations fund ii llc palantir series  nam special situations fund iii llc magic leap series  nam special situations fund i qp llc lyft series iii nam biotech fund ii llc series i last visited companies behringer harvard holdings llc beartooth capital ii lp benchmark capital partners vii lp benchmark founders fund vii lp brawley bliss llc  whoisraisingmoneycom daily updated news about investment into startups hedge funds and private equity companies nam special situations fund i llc  list of ceos founders and company directors directorpedianet  list of ceos founders board members and company directors nam special situations fund i llc list of persons related to the company nam special situations fund i llc find out list of ceos founders board members and company directors of nam special situations fund i llc cik number irs number company address  park avenue th floor new york phone number  people related to nam special situations fund i llc namepositionstreetcitycountrylevine david n military trail aptboca ratonflgoldwasser mark park avenue th floor new yorknylerner william vista valley road washingtonpa nam special situations fund i llc on the web related companiesnam biotech fund ii llc series i nam biotech fund ii llc series iii nam biotech fund ii llc series iv nam biotech fund ii llc  series ii nam special situations fund i qp llc nam special situations fund i qp llc fbio series i nam special situations fund i qp llc lyft series iii nam special situations fund i qp llc lyft series iv nam special situations fund i qp llc palantir series  nam special situations fund i qp llc  fbio series ii nam special situations fund i qp llc  fbio series iv nam special situations fund i qp llc fbio series iii nam special situations fund ii llc palantir series  nam special situations fund iii llc magic leap series  namaste solar electric inc nam special situations fund i qp llc palantir series  financing  newest sec filings newest filings nam special situations fund i qp llc palantir series  financing nam special situations fund i qp llc palantir series  just submitted form d announcing indefinite financing this is a new filing nam special situations fund i qp llc palantir series  was able to sell  the total private offering amount was indefinite the financing was made by  investors minimal accepted investment was  the financing document was filed on  nam special situations fund i qp llc palantir series  is based in co national securities corporation  park avenue th floor new york  the firms business is pooled investment fund the firms revenue range is decline to disclose the form was signed by  nam special situations management llc sec form d the securities and exchange commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and completethe reader should not assume that the information is accurate and complete united states securities and exchange commissionwashington dc form dnotice of exempt offering of securities omb approval omb number  estimated average burden hours per response   issuers identity cik filer id number previous names x none entity type     corporation    limited partnership x limited liability company    general partnership    business trust    other specify name of issuer nam special situations fund i qp llc palantir series  jurisdiction of incorporationorganization delaware year of incorporationorganization    over five years ago x within last five years specify year     yet to be formed  principal place of business and contact information name of issuer nam special situations fund i qp llc palantir series  street address  street address  co national securities corporation  park avenue th floor city stateprovincecountry zippostalcode phone number of issuer new york new york    related persons last name first name middle name nam special situations management llc  street address  street address   park avenue th floor city stateprovincecountry zippostalcode new york new york  relationship x executive officer    director    promoter clarification of response if necessary manager last name first name middle name national asset management inc  street address  street address   park avenue th floor city stateprovincecountry zippostalcode new york new york  relationship x executive officer    director    promoter clarification of response if necessary advisor last name first name middle name levine david street address  street address  co national asset management inc  park avenue th floor city stateprovincecountry zippostalcode new york new york  relationship x executive officer    director    promoter clarification of response if necessary  industry group    agriculture banking  financial services    commercial banking    insurance    investing    investment banking x pooled investment fund    hedge fund x private equity fund    venture capital fund    other investment fund is the issuer registered as an investment company under the investment company act of     yes x no    other banking  financial services    business services energy    coal mining    electric utilities    energy conservation    environmental services    oil  gas    other energy health care    biotechnology    health insurance    hospitals  physicians    pharmaceuticals    other health care    manufacturing real estate    commercial    construction    reits  finance    residential    other real estate    retailing    restaurants technology    computers    telecommunications    other technology travel    airlines  airports    lodging  conventions    tourism  travel services    other travel    other  issuer size revenue range or aggregate net asset value range    no revenues    no aggregate net asset value                                                    over     over  x decline to disclose    decline to disclose    not applicable    not applicable  federal exemptions and exclusions claimed select all that apply    rule b not i ii or iii    rule  bi    rule  bii    rule  biii    rule  x rule b    rule c    securities act section a x investment company act section c    section c    section c      section c    section c    section c    section c    section c    section c    section c    section c    section c    section c x section c  type of filing x new notice date of first sale x first sale yet to occur    amendment  duration of offering does the issuer intend this offering to last more than one year    yes x no  types of securities offered select all that apply    equity x pooled investment fund interests    debt    tenantincommon securities    option warrant or other right to acquire another security    mineral property securities    security to be acquired upon exercise of option warrant or other right to acquire security    other describe  business combination transaction is this offering being made in connection with a business combination transaction such as a merger acquisition or exchange offer    yes x no clarification of response if necessary  minimum investment minimum investment accepted from any outside investor  usd  sales compensation recipient recipient crd number    none national securities corporation  associated broker or dealer x none associated broker or dealer crd number x none none none street address  street address  one union square  university street suite  city stateprovincecountry zippostal code seattle washington  states of solicitation select all that applycheck “all states” or check individual states x all states    foreignnonus  offering and sales amounts total offering amount usd or x indefinite total amount sold  usd total remaining to be sold usd or x indefinite clarification of response if necessary  investors    select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors and enter the number of such nonaccredited investors who already have invested in the offering regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors enter the total number of investors who already have invested in the offering   sales commissions  finders fees expenses provide separately the amounts of sales commissions and finders fees expenses if any if the amount of an expenditure is not known provide an estimate and check the box next to the amount sales commissions  usd x estimate finders fees  usd    estimate clarification of response if necessary assumes maximum commissions earned use of proceeds provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers directors or promoters in response to item  above if the amount is unknown provide an estimate and check the box next to the amount  usd x estimate clarification of response if necessary signature and submission please verify the information you have entered and review the terms of submission below before signing and clicking submit below to file this notice terms of submission in submitting this notice each issuer named above is notifying the sec andor each state in which this notice is filed of the offering of securities described and undertaking to furnish them upon written request in the accordance with applicable law the information furnished to offerees irrevocably appointing each of the secretary of the sec and the securities administrator or other legally designated officer of the state in which the issuer maintains its principal place of business and any state in which this notice is filed as its agents for service of process and agreeing that these persons may accept service on its behalf of any notice process or pleading and further agreeing that such service may be made by registered or certified mail in any federal or state action administrative proceeding or arbitration brought against it in any place subject to the jurisdiction of the united states if the action proceeding or arbitration a arises out of any activity in connection with the offering of securities that is the subject of this notice and b is founded directly or indirectly upon the provisions of  i the securities act of  the securities exchange act of  the trust indenture act of  the investment company act of  or the investment advisers act of  or any rule or regulation under any of these statutes or ii the laws of the state in which the issuer maintains its principal place of business or any state in which this notice is filed certifying that if the issuer is claiming a regulation d exemption for the offering the issuer is not disqualified from relying on regulation d for one of the reasons stated in rule biii or rule d each issuer identified above has read this notice knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person for signature type in the signers name or other letters or characters adopted or authorized as the signers signature issuer signature name of signer title date nam special situations fund i qp llc palantir series  s david levine david levine ceo of the advisor  persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid omb number  this undertaking does not affect any limits section a of the national securities markets improvement act of  nsmia pub l no   stat  oct   imposes on the ability of states to require information as a result if the securities that are the subject of this form d are covered securities for purposes of nsmia whether in all instances or due to the nature of the offering that is the subject of this form d states cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent nsmia permits them to do so under nsmias preservation of their antifraud authority nam special situations fund i qp llc palantir series  financing datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions new form dindefiniteyet to sellindefiniteb c cview nam special situations fund i qp llc palantir series  list of executives nam special situations management llc  national asset management inc david levine last visited kirk  associates llc kiromic llc kiromic llc kiromic llc kiwitech llc    fortress biotech inc nasdaqfbio files an k entry into a material definitive agreement  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east� more equities indexes dow jonessp nasdaq tsx compftse � more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd� more currencies commodities goldcrude oil wticrude oil brentsilverplatinum� more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    fortress biotech inc    cndo fortress biotech inc cndo add to my list    mes derni�res consultmost popular manage my lists  delayed     pm  usd     fortress biotec  fbio files an k departure of directors or certa  fortress biotec  to present at the  bio international conventio  fortress biotec  subsidiary caelum biosciences enters biopharmaceut summaryquoteschartsnewscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets fortress biotech inc nasdaqfbio files an k entry into a material definitive agreement    pm cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields fortress biotech inc nasdaqfbio files an k entry into a material definitive agreementitem  entry into a material definitive agreement the information set forth under item  of this current report on form k regarding the transaction documents as such term is defined in item  below is incorporated herein by reference item  creation of a direct financial obligation or an obligation under an offbalance sheet arrangement of a registrant the information set forth under item  of this current report on form k regarding the transaction and transaction documents as such terms are defined in item  below is incorporated herein by reference item  unregistered sales of equity securities on march   fortress biotech inc the “company” entered into note purchase agreements the “purchase agreements” with nam biotech fund ii llc – series i “nam biotech fund” and nam special situations fund i qp llc – fbio series i “nam special situations fund” both of which are accredited investors and sold subordinated promissory notes the “notes” of the company the “transaction” in the aggregate principal amount of  million the notes bear interest at the rate of  per annum additionally the notes accrue paidinkind interest at the rate of  per annum which will be paid quarterly in shares of the company’s common stock andor shares of common stock of one of the company’s subsidiaries that are publicly traded in accordance with the terms of the notes each note is due on the third anniversary of its issuance provided that the company may extend the maturity date for two oneyear periods in its sole discretion in accordance with the terms of the notes the transaction is for a minimum of  million and a maximum of  million which the company may in its sole discretion increase to  million national securities corporation “nsc” to a placement agency agreement previously entered into between the company nam biotech fund and nsc the “nam placement agency agreement” and a placement agency agreement previously entered into between the company nam special situations fund and nsc together with the nam placement agency agreement the “placement agency agreements” acts as placement agent in the transaction to the terms of the placement agency agreements nsc receives in addition to reimbursement of certain expenses an aggregate cash fee equal to  of the aggregate sales price of the notes sold in the transaction to nam biotech fund and nam special situations fund the placement agent also receives warrants equal to  of the aggregate principal amount of the notes sold in the transaction to nam biotech fund and nam special situations fund divided by the closing share price of the company on the date of closing the “placement agent warrants” and collectively with the purchase agreements notes and placement agency agreements the “transaction documents” the placement agent warrants are exercisable immediately in cash at such closing share price for a period of five years the placement agent will have a right of first offer for a period of  months for any proposed issuance of the company’s capital stock in a private financing subject to certain exceptions and will also have the right to participate as an investor in subsequent financings in connection with the initial closing of the transaction nsc received a cash fee of  and a placement agent warrant to purchase  shares of the company’s common stock in september  the company purchased  of the outstanding shares of common stock of national holdings inc “nhld” since nsc is a subsidiary of nhld a majority of the disinterested directors of the company’s board of directors approved the transaction and transaction documents the foregoing summary of the material terms of the transaction documents is subject to the full and complete terms of such transaction documents the placement agency agreements and form of placement agent warrant purchase agreement and note will be filed with the company’s quarterly report on form q for the quarter ended march   the notes and placement agent warrants were sold in a private placement to exemptions from the registration requirements of the securities act of  as amended the “securities act” afforded by section a and rule  of regulation d promulgated thereunder to the extent that any shares of company common stock are issued in connection with the placement agent warrants and notes they may not be offered or sold in the united states absent registration or the availability of an applicable exemption from the registration requirements of the securities act the information contained in this current report on form k is not an offer to sell or the solicitation of an offer to buy any securities of the company about fortress biotech inc nasdaqfbio fortress biotech inc formerly coronado biosciences inc is a biopharmaceutical company the company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer its sole product candidate is cndo the company is also focused on acquiring developing and commercializing pharmaceutical and biotechnology products the company’s product cndo is a lysate disrupted closteroviridae ctv cells cell membrane fragments cell proteins and other cellular components that activates donor natural killer nk cells ctv is a leukemic cell line reclassified as a tcell acute lymphocytic leukemia all the company holds the license to develop and commercialize cndo to activate nk cells for the treatment of cancerrelated and other conditions and a nonexclusive license to certain clinical data solely for use in the investigational new drug ind for cndo the company is conducting the phase i clinical studies of cndo fortress biotech inc nasdaqfbio recent trading information fortress biotech inc nasdaqfbio closed its last trading session down  at  with  shares trading hands the post fortress biotech inc nasdaqfbio files an k entry into a material definitive agreement appeared first on market exclusive market exclusive  source market exclusive  latest news on fortress biotech inc  fortress biotech  announces provisional patent application for cael  fortress biotech  appoints new president and ceo for subsidiary avenue therapeu  fortress biotech inc nasdaq  fbio files an k departure of directors or ce  fortress biotech inc  change in directors or principal officers form k  fortress biotech  to present at the  bio international convention  fortress biotech inc  change in directors or principal officers submission o  fortress biotech  subsidiary caelum biosciences enters biopharmaceutical manufa  fortress biotech inc nasdaq  fbio files an k results of operations and fi  fortress biotech  reports q loss  fortress biotech inc  results of operations and financial condition financia more news news from seekingalpha  fortress biotech misses by   premarket biotech digest  alzheimers conference gilead new odd axovant pops  fortress biotech acquires rare disease product candidate from new zealand pha  is fortress staging to buy out its former partners  cormedix  strong sell on partner failure misleading data and paid stock promot financials  sales   m ebit   m net income   m debt   yield   pe ratio   pe ratio  capi  sales  x capi  sales  x capitalization  m more financials chart fortress biotech inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends fortress biotech inc short termmidtermlong termtrendsneutralbullishbullish technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus outperform number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitlelindsay allan rosenwald chairman president  chief executive officer robyn hunter chief financial officer eric k rowinsky vice chairman jimmie harvey independent director j jay lobell independent director more about the company sector and competitors st jancapitalization m fortress biotech inc biogen  csl limited  alexion pharmaceuticals  grifols sa  biomarin pharmaceutical  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners b�rse aktien kurse und nachrichtenbest tweets copyright �  surperformance all rights reserved slave fortress biotech inc  entry into a material definitive agreement creation of a direct financial obligation or an obligation under an offbalance sheet arrangement of a registrant unregistered sale of equity securities form k  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east� more equities indexes dow jonessp nasdaq tsx compftse � more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd� more currencies commodities goldcrude oil wticrude oil brentsilverplatinum� more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    fortress biotech inc    cndo fortress biotech inc cndo add to my list    mes derni�res consultmost popular manage my lists  delayed     pm  usd     fortress biotec  fbio files an k departure of directors or certa  fortress biotec  to present at the  bio international conventio  fortress biotec  subsidiary caelum biosciences enters biopharmaceut summaryquoteschartsnewscalendarcompanyfinancialsconsensusrevisions news summarymost relevantall newssector newstweets fortress biotech inc  entry into a material definitive agreement creation of a direct financial obligation or an obligation under an offbalance sheet arrangement of a registrant unregistered sale of equity securities form k    pm cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields item  entry into a material definitive agreement the information set forth under item  of this current report on form k regarding the transaction documents as such term is defined in item  below is incorporated herein by reference item  creation of a direct financial obligation or an obligation under an offbalance sheet arrangement of a registrant the information set forth under item  of this current report on form k regarding the transaction and transaction documents as such terms are defined in item  below is incorporated herein by reference item  unregistered sales of equity securities on march   fortress biotech inc the company entered into note purchase agreements the purchase agreements with nam biotech fund ii llc  series i nam biotech fund and nam special situations fund i qp llc  fbio series i nam special situations fund both of which are accredited investors and sold subordinated promissory notes the notes of the company the transaction in the aggregate principal amount of  million the notes bear interest at the rate of  per annum additionally the notes accrue paidinkind interest at the rate of  per annum which will be paid quarterly in shares of the companys common stock andor shares of common stock of one of the companys subsidiaries that are publicly traded in accordance with the terms of the notes each note is due on the third anniversary of its issuance provided that the company may extend the maturity date for two oneyear periods in its sole discretion in accordance with the terms of the notes the transaction is for a minimum of  million and a maximum of  million which the company may in its sole discretion increase to  million national securities corporation nsc pursuant to a placement agency agreement previously entered into between the company nam biotech fund and nsc the nam placement agency agreement and a placement agency agreement previously entered into between the company nam special situations fund and nsc together with the nam placement agency agreement the placement agency agreements acts as placement agent in the transaction pursuant to the terms of the placement agency agreements nsc receives in addition to reimbursement of certain expenses an aggregate cash fee equal to  of the aggregate sales price of the notes sold in the transaction to nam biotech fund and nam special situations fund the placement agent also receives warrants equal to  of the aggregate principal amount of the notes sold in the transaction to nam biotech fund and nam special situations fund divided by the closing share price of the company on the date of closing the placement agent warrants and collectively with the purchase agreements notes and placement agency agreements the transaction documents the placement agent warrants are exercisable immediately in cash at such closing share price for a period of five years the placement agent will have a right of first offer for a period of  months for any proposed issuance of the companys capital stock in a private financing subject to certain exceptions and will also have the right to participate as an investor in subsequent financings in connection with the initial closing of the transaction nsc received a cash fee of  and a placement agent warrant to purchase  shares of the companys common stock in september  the company purchased  of the outstanding shares of common stock of national holdings inc nhld since nsc is a subsidiary of nhld a majority of the disinterested directors of the companys board of directors approved the transaction and transaction documents the foregoing summary of the material terms of the transaction documents is subject to the full and complete terms of such transaction documents the placement agency agreements and form of placement agent warrant purchase agreement and note will be filed with the companys quarterly report on form q for the quarter ended march   the notes and placement agent warrants were sold in a private placement pursuant to exemptions from the registration requirements of the securities act of  as amended the securities act afforded by section a and rule  of regulation d promulgated thereunder to the extent that any shares of company common stock are issued in connection with the placement agent warrants and notes they may not be offered or sold in the united states absent registration or the availability of an applicable exemption from the registration requirements of the securities act the information contained in this current report on form k is not an offer to sell or the solicitation of an offer to buy any securities of the company edgar online source glimpses  latest news on fortress biotech inc  fortress biotech  announces provisional patent application for cael  fortress biotech  appoints new president and ceo for subsidiary avenue therapeu  fortress biotech inc nasdaq  fbio files an k departure of directors or ce  fortress biotech inc  change in directors or principal officers form k  fortress biotech  to present at the  bio international convention  fortress biotech inc  change in directors or principal officers submission o  fortress biotech  subsidiary caelum biosciences enters biopharmaceutical manufa  fortress biotech inc nasdaq  fbio files an k results of operations and fi  fortress biotech  reports q loss  fortress biotech inc  results of operations and financial condition financia more news news from seekingalpha  fortress biotech misses by   premarket biotech digest  alzheimers conference gilead new odd axovant pops  fortress biotech acquires rare disease product candidate from new zealand pha  is fortress staging to buy out its former partners  cormedix  strong sell on partner failure misleading data and paid stock promot financials  sales   m ebit   m net income   m debt   yield   pe ratio   pe ratio  capi  sales  x capi  sales  x capitalization  m more financials chart fortress biotech inc duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends fortress biotech inc short termmidtermlong termtrendsneutralbullishbullish technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials consensus sell buy mean consensus outperform number of analysts  average target price   spread  average target  consensus details eps revisions please enable javascript in your browsers settings to use dynamic charts more estimates revisions managers nametitlelindsay allan rosenwald chairman president  chief executive officer robyn hunter chief financial officer eric k rowinsky vice chairman jimmie harvey independent director j jay lobell independent director more about the company sector and competitors st jancapitalization m fortress biotech inc biogen  csl limited  alexion pharmaceuticals  grifols sa  biomarin pharmaceutical  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners b�rse aktien kurse und nachrichtenbest tweets copyright �  surperformance all rights reserved slave